[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633019":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":24,"id":49,"slug":24,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":24,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":24,"studyType":62,"phases":63,"briefSummary":52,"conditions":65,"keywords":24,"overallStatus":67,"whyStopped":24,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference drug(AD-2301), Period 2 : Test drug(AD-230) Single oral dose administration of AD-2301 three times in Period 1, followed by single oral dose administration of AD-230 twice in Period 2.",[13],"Drug: AD-230, AD-2301",{"label":15,"type":10,"description":16,"interventionNames":17},"Sequence B","Period 1 : Test drug(AD-230), Period 2 : Reference drug(AD-2301) Single oral dose administration of AD-230 twice in Period 1, followed by single oral dose administration of AD-2301 three times in Period 2",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","AD-230, AD-2301","Oral administration of AD-230 or AD-2301, according to randomized sequence.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Sarah Yoon","CONTACT","031-891-5576","sryoon@addpharma.co.kr",[32],{"facility":33,"status":24,"city":34,"state":24,"zip":24,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Kyungpook National university hospital","Seoul","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},[43],{"name":44,"role":28,"phone":45,"phoneExt":24,"email":46},"Young-Ran Yoon","+82-53-420-4950","yry@knu.ac.kr",{"type":48,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100633019",false,"NCT07521241","A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","Inclusion Criteria:\n\n* \\- Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":60,"type":61},52,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1",[66],"Chronic Liver Disease (CLD)","NOT_YET_RECRUITING","2026-04-08",{"date":70,"type":71},"2026-04-13","ACTUAL",{"date":73,"type":61},"2026-05",{"date":75,"type":61},"2026-07",{"name":5,"class":6},1]